-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight, Announces $10 Price Target

Benzinga·05/15/2025 15:28:21
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Overweight and announces $10 price target.